Financial Performance - The company's revenue for Q1 2025 reached CNY 984.87 million, a 75.76% increase compared to CNY 560.33 million in the same period last year[5]. - Net profit attributable to shareholders was CNY 311.92 million, reflecting a significant increase of 224.90% from CNY 96.00 million year-on-year[5]. - The net profit excluding non-recurring gains and losses was CNY 214.65 million, up 1,150.17% from CNY 17.17 million in the previous year[5]. - Basic earnings per share rose to CNY 0.53, representing a 231.25% increase from CNY 0.16 year-on-year[5]. - Total operating revenue for Q1 2025 reached ¥984.87 million, a significant increase of 75.7% compared to ¥560.33 million in Q1 2024[21]. - Net profit for Q1 2025 was ¥311.92 million, up 225.5% from ¥96.00 million in Q1 2024[21]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.53, compared to ¥0.16 in Q1 2024[22]. - The company reported a total profit of ¥360.39 million for Q1 2025, compared to ¥113.56 million in Q1 2024, reflecting a growth of 217.5%[21]. - The company’s total comprehensive income for Q1 2025 was ¥312.26 million, compared to ¥95.89 million in Q1 2024, marking a growth of 226.5%[21]. Cash Flow and Assets - Cash flow from operating activities was CNY 158.75 million, a 95.29% increase compared to CNY 81.29 million in the same period last year[5]. - Cash flow from operating activities for Q1 2025 was ¥158.75 million, an increase of 95.5% from ¥81.29 million in Q1 2024[23]. - The company's total assets increased by 2.01% to CNY 12.28 billion compared to the end of the previous year[5]. - The company's total assets as of March 31, 2025, amount to ¥12,284,434,818.79, an increase from ¥12,042,916,391.88 at the end of 2024[18][19]. - Current assets total ¥3,900,272,940.75, showing an increase from ¥3,790,858,209.05[18]. - The company's cash and cash equivalents stand at ¥1,058,837,161.68, up from ¥902,777,760.68[18]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥372.30 million, up from ¥337.92 million at the end of Q1 2024[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 74,987[15]. - The largest shareholder, Gan Zhongru, holds 205,643,757 shares, accounting for 34.21% of total shares[15]. - The company has pledged 28,210,000 shares held by Gan Zhongru[15]. - The equity attributable to shareholders of the parent company is ¥11,312,123,449.60, compared to ¥11,054,470,662.18 previously[19]. - The company has no significant changes in shareholder relationships or actions during the reporting period[17]. Sales Performance - Domestic sales revenue was CNY 889 million, up 80.07% from the previous year, driven by significant growth in insulin product sales[12]. - International sales revenue reached CNY 95 million, a 45.21% increase compared to the same period last year, supported by expanding international market efforts[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥739.37 million, an increase of 36.4% from ¥541.95 million in Q1 2024[21]. - Research and development expenses for Q1 2025 were ¥130.45 million, slightly down from ¥133.12 million in Q1 2024[21]. Future Plans - The company plans to continue deepening its global layout and drive export business growth through innovation[14]. Inventory and Liabilities - The company reported an increase in inventory to ¥1,113,062,811.37 from ¥1,052,906,832.75[18]. - Total liabilities decreased to ¥972,311,369.19 from ¥988,445,729.70[19].

Financial Performance - In 2023, the company achieved a revenue of CNY 3,045.35 million, representing a year-on-year growth of 16.77%[7] - The net profit attributable to shareholders reached CNY 614.66 million, with a significant year-on-year increase of 80.75%[7] - The company reported a significant focus on innovative drug development, with multiple products in the pipeline[26] - The company achieved a revenue of 3,045.35 million yuan in 2024, representing a year-on-year growth of 16.77%, and a net profit attributable to shareholders of 614.66 million yuan, up 80.75% year-on-year[46] - The net profit attributable to shareholders for 2024 was approximately CNY 614.66 million, a significant increase of 80.75% from CNY 340.07 million in 2023[36] - The company reported a significant increase in R&D investment for the GZR18 injection, totaling RMB 15,112.94 million, with a year-on-year increase of 63.87%[172] - The company achieved an EBITDA of CNY 798 million, which is a 74.92% increase compared to the previous year[132] Market Position and Strategy - The market share in the domestic market rose to the second position in the industry, only behind Novo Nordisk, covering 41,000 medical institutions[7] - The company aims to transition from "China manufacturing" to "global innovation," focusing on high-quality development and patient-centered approaches[4] - The company is actively expanding its international market presence, including establishing a local insulin production facility in Brazil[10] - The company aims to enhance its global brand influence and market share by launching new products like GZR18 and GZR4, which are expected to diversify treatment options for diabetes patients[109] - The company is focusing on expanding its product line by actively seeking external quality targets in addition to self-developed new drugs[189] Research and Development - Research and development investment reached CNY 646 million, accounting for 21.20% of total revenue[9] - The company is advancing its innovative insulin products, with GZR4 and GZR18 entering critical clinical phases, showing promising results in efficacy[9] - The company is developing GZR101, a novel combination insulin product, aimed at diabetes treatment[25] - GZR33, a long-acting insulin analog, is also under development, expected to enhance diabetes management[25] - The company has established a comprehensive R&D management system, ensuring projects meet expected goals through various research phases from target research to clinical trials[118] Clinical Trials and Approvals - The company completed the Phase II clinical study of GZR18 injection, showing superior efficacy in reducing HbA1c and weight compared to Semaglutide after 24 weeks of treatment[48] - GZR4 injection also achieved primary endpoints in Phase II clinical trials, demonstrating better efficacy in lowering HbA1c compared to Degludec after 16 weeks of treatment[48] - The company received FDA preliminary feedback and passed EMA's GMP inspection, marking a significant milestone for its insulin products in the EU market[47] - The company received approval from the China CDE for the III phase clinical study of Bofanglupatide for obesity/overweight in December 2024, with the first subject dosed successfully[56] - The company’s GZR4 injection has also been approved for Phase III clinical research in China, with the first patient dosing completed in February 2025[167] Procurement and Supply Chain - The company secured a procurement agreement for 46.86 million units of insulin, marking a 32.6% increase compared to the previous procurement cycle[7] - The insulin procurement cycle initiated in May 2022 will last for two years, impacting pricing strategies[25] - The new insulin procurement policy announced in March 2024 will extend until December 31, 2027, indicating a long-term strategy[25] - The company successfully participated in the national drug centralized procurement for insulin, resulting in a price adjustment that positively impacted overall revenue by CNY 315 million[140] - The company has established a production partnership in Brazil, marking a significant milestone in local insulin production capabilities[80] Talent and Human Resources - A restricted stock incentive plan was implemented to enhance talent retention and drive long-term development[10] - The company has implemented a comprehensive talent development strategy, focusing on nurturing management personnel across all levels to support international growth[90] - The company has established long-term partnerships with major universities to build a talent pool, enhancing its brand influence in the academic community[91] - The company has received multiple employer brand awards, including Forbes' Top 100 Returnees and Best Employers, which enhances its attractiveness to talent[92] Regulatory Compliance and Risk Management - The board of directors confirmed the authenticity, accuracy, and completeness of the annual report, ensuring no significant omissions or misleading statements[14] - There are no significant risks that could materially affect the company's operations during the reporting period[19] - The company is closely monitoring policies related to grassroots healthcare services and plans to increase R&D investment to improve service quality for diabetes patients in rural areas[100] - The company faces industry policy risks due to increasing regulatory scrutiny and the implementation of various healthcare policies in China[188] Financial Management and Investments - The company has distributed a total cash dividend of CNY 1.613 billion since its IPO in 2020, with a projected dividend of CNY 899 million for 2024, representing 146.31% of the net profit attributable to ordinary shareholders for that year[93] - The company’s financial disclosures are available through Shanghai Securities News and China Securities Journal[31] - The company has engaged Deloitte as its accounting firm, ensuring compliance and oversight[33] - The company is committed to high-quality sustainable development and cost control to maximize enterprise benefits and create continuous value for shareholders[93] International Expansion - The company is actively expanding its international market presence, particularly in emerging markets along the "Belt and Road" initiative[78] - The company received regulatory approval for its insulin products in Malaysia, marking a significant milestone in its international expansion strategy in Southeast Asia[81] - The internationalization strategy is focused on expanding overseas markets to ensure a steady supply of insulin and reduce healthcare costs for diabetes patients globally[187] Product Development and Innovation - The company has a robust pipeline with multiple products in clinical stages, including GZR18 and GZR4, focusing on diabetes and obesity treatment[50] - The company’s innovative approach in developing oral GLP-1RA formulations reflects its commitment to improving patient experience and treatment adherence[59] - The company is focusing on research in various fields, including oncology and cardiovascular diseases, to provide a broader range of treatment options[109] - The company has successfully developed multiple third-generation insulin analogs, positioning itself as a leader in the domestic insulin production industry[110]

独立董事候选人声明与承诺 本人昌增益，已充分了解并同意由甘李药业股份有限公司董事会提名为甘李 药业股份有限公司第五届董事会独立董事候选人。本人公开声明， 本人具备独立 董事任职资格，保证不存在任何影响本人担任甘李药业股份有限公司独立董事独 立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识， 熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。本人已取得上海证券交易所独立董事资格证 书。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企 ...

一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 公司代码：603087 公司简称：甘李药业 甘李药业股份有限公司 2024年度内部控制评价报告 甘李药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合甘李药业股份有限公司（以下简称公司）内 ...

甘李药业股份有限公司 经核查独立董事何艳青、郑国钧、昌增益的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司控股股东、实际控 制人的附属企业担任任何职务，与公司以及主要股东、实际控制人之间不存在利害 关系或其他可能妨碍其进行独立客观判断的关系。因此，公司董事会认为，公司独 立董事符合《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等规定中对独立董事独立性的相关要求。 特此报告。 甘李药业股份有限公司 董事会 2025 年 4 月 25 日 董事会对独立董事独立性自查情况的专项报告 根据中国证监会《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》等规定，甘李药业股份有限公司（以下简称"公 司"）董事会，就公司在任独立董事何艳青、郑国钧、昌增益的独立性情况进行评 估并出具如下专项意见： ...

一、本人具备上市公司运作的基本知识， 熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。本人已取得上海证券交易所独立董事资格证 书。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； 独立董事候选人声明与承诺 本人杜鸿玭，已充分了解并同意由甘李药业股份有限公司董事会提名为甘李 药业股份有限公司第五届董事会独立董事候选人。本人公开声明， 本人具备独立 董事任职资格，保证不存在任何影响本人担任甘李药业股份有限公司独立董事独 立性的关系，具体声明并承诺如下： （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企 ...

中信证券股份有限公司 关于甘李药业股份有限公司 2024 年度募集资金存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为甘李 药业股份有限公司（以下简称"甘李药业"或"公司"）首次公开发行股票并在 上海证券交易所主板上市的保荐机构，根据《中华人民共和国证券法》、《证券 发行上市保荐业务管理办法》、《上海证券交易所股票上市规则》等相关规定， 对公司 2024 年度募集资金存放与使用情况进行了专项核查，具体情况如下： 一、募集资金基本情况 （一）2020 年首次公开发行股票募集资金基本情况 经中国证券监督管理委员会以"证监许可[2020]1075 号"文《关于核准甘李 药业股份有限公司首次公开发行股票的批复》核准，公司向社会公开发行人民币 普通股 40,200,000 股（A 股），每股面值人民币 1 元，发行价格为人民币 63.32 元/股，募集资金总额为人民币 2,545,464,000.00 元。扣减发行上市费用人民币 104,329,536.23 元（由于本公司对外销售自产的胰岛素产品按 3%的简易征收率 缴纳增值税，不予抵扣进项税，上述发行费用包含增值税金）后， ...

独立董事候选人声明与承诺 一、本人具备上市公司运作的基本知识, 熟悉相关法律、行政法规、部门规 章及其他规范性文件,具有 5年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。本人承诺将会参加上海证券交易所举办的最 近一期独立董事任职资格培训。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求; (一) 《中华人民共和国公司法》关于董事任职资格的规定: (二) 《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）; (三)中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定; (四)中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 (离) 休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用); (五)中共中央组织部《关于进一步规范党政领导干部在企业兼职(任职) 问题的意见》的相关规定; (六)中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定; 本人刘俊义,已充分了解并同意由甘李药业股份有限公司董事会提名为甘李 药业股份有限公司第五届 ...

甘李药业股份有限公司 2024 年度会计师事务所履职情况评估报告 甘李药业股份有限公司（以下简称"公司"）聘请致同会计师事务所（特 殊普通合伙）（以下简称"致同会计师事务所"）作为公司 2024 年度财务报告 审计机构、内部控制审计机构。根据《国有企业、上市公司选聘会计师事务所 管理办法》，公司对致同会计师事务所 2024 年审计过程中的履职情况进行评估。 经评估，公司认为致同会计师事务所资质等方面合规有效，履职保持独立性， 勤勉尽责，公允出具意见，具体情况如下： 一、资质条件 致同会计师事务所于 2011 年 12 月 22 日获批准执业，办公地址为北京市朝 阳区建国门外大街 22 号赛特广场 5 层，首席合伙人为李惠琦。截至 2024 年末， 致同会计师事务所合伙人数量 239 名，注册会计师数量 1,359 名。致同会计师 事务所 2023 年度业务收入 270,337.32 万元，其中审计业务收入 220,459.50 万元， 证券业务收入 50,183.34 万元。 二、执业记录 （一）基本信息 项目合伙人：钱华丽，2007 年成为注册会计师，2007 年开始从事上市公司 审计业务，2015 年开始 ...

甘李药业（603087）公告，2025年第一季度营业收入为9.85亿元，同比增长75.76%。净利润为3.12亿 元，同比增长224.90%。 ...